Summary
The evidence-based medicine movement has these limitations, decision analysis, a technique which allows to consider multiple health outcomes, received enthusiastic endorsement from editors of major medical journals. Hardly anyone can disagree such as the patient's preferences for different states of health, and to measure the consequences of many with the aim of helping clinicians to make judicious use of the best scientific evidence for decisions in strategies for which randomized trials are not feasible, provides a rational means of allowing health patient care. Evidence-based medicine, however, because of its dependence on randomized trials, professionals to move from finding evidence to implementing it. Such formal approach may reconcannot be applied to all individuals seen in daily practice. Specifically, patients may differ in age, cile evidence-based medicine with 'real life' and patient's preference. It should therefore be considseverity of illness, presence of comorbidity and myriad of other clinical nuances. In response to ered complementary to evidence-based medicine.
Applying evidence-based medicine to individual patients
There is increasing pressure on health-care profescurrently published in the EBM journals. To determine the efficacy of treatments, results are usually sionals to ensure that their practice is based on evidence from good quality research, such as ranexpressed as the odds or risk of outcome events in the experimental group compared with a control domized controlled trials, or systematic reviews of randomized controlled trials (e.g. meta-analyses).
group, e.g. the relative reduction in odds or risk. It is then generally considered that the relative treatConsequently, the 'evidence-based medicine' (EBM) movement, which encourages the use of current best ment effect is generalizable to all patients in the trial and all similar future patients.3 This assumption, evidence in making decisions about the care of individual patients, has established its own journal which is convenient, simplifies a complex problem encountered by all physicians in their daily activities, and received enthusiastic endorsement from editors of major medical journals.1,2 Hardly anyone can which is that of applying average group-derived data (e.g. 'on average' treatment estimate) to a unique disagree with the aim of helping clinicians to make judicious use of the best scientific evidence for patient.4,5 EBM, however, because of its dependence on randomized controlled trials and meta-analyses, decisions in patient care.
An almost exclusive focus on randomized clinical cannot be simply applied to all individuals seen in clinical practice. Derived from a non-representative, trials and meta-analyses is evident in the material carefully selected population that is confined to quality-adjusted life expectancy and the number of adverse events associated with each strategy have patients expected to be highly responsive to treatment, overall results may not be always pertinent for been detailed elsewhere.11 Based on randomized controlled trials, our patients seen in everyday practice. Specifically, patients may differ in age, severity of illness, presence patient's presumed rate of systemic embolism without anticoagulation therapy is about 5%/year, that of of comorbidity and myriad other clinical nuances.
major haemorrhage 1.3%/year, while anticoagulation therapy provides a relative risk reduction for embolism of 68%.12 Thus, the expected outcome of thera-
Approaches to individualizing
peutic abstention expressed in quality-adjusted-lifedecision-making years (QALYs) is 8.6 QALYs, while that of anticoagulation therapy is 9.3 QALYs, a gain of 8%. In Glasziou et al. have proposed criteria for applying population-based studies of patients receiving anticoaverage group-derived data to individual patients: agulant therapy outside of trials, however, the excess (i) stratification of findings according to patients risk for bleeding was higher, around 3%/year.13 characteristics, (ii) assessment of whether the Should anticoagulation still be given? To what extent intervention can be approximated in a non-study can this change modify the preferred option and setting, (iii) quantification of benefits and harm, eventually lead to withhold therapy? The process of and (iv) incorporation of individual preferences. 6, 7 examining the clinical implications of variations in Although such a formal approach may be helpful, the baseline scenario is called sensitivity analysis. we would like to emphasize the usefulness of clinical By varying probabilities, it is possible to see how a decision analysis in relating the average results from decision would change, that is, how robust it is. Our a trial to a particular patient. Formal decision analysis model shows that anticoagulation is preferable as uses probabilities together with values assigned to long as the rate of bleeding remains below 12%/year different outcomes to determine the best course of ('threshold' value), a value well above most estimaction.8,9 Specifically, for a therapeutic choice involates. However, the gain in QALYs decreased from ving substantial change in absolute benefit or risk 10% to 6% (rate of bleeding 3%/year), a useful piece compared with predicted results, it can examine the of information. The patient says that she is terrified tradeoffs between these risks and benefits. In addiof having a haemorrhagic stroke. What should be tion, this technique allows to consider multiple done? A utility represents a patient's preference for attributes of health outcomes, such as the patient's one outcome over others and is given a numerical preferences for different states of health, and to value which is then used in the decision analysis.14,15 measure the consequences of many strategies for Values are usually quantified on a scale from zero which randomized trials are not feasible.8,9
to one. Thus, even if you assume a strong desire to avoid the disability associated with haemorrhagic stroke, giving it a utility of 0.1, our model suggests
An example of decision analysis
that the choice of anticoagulant therapy remains the preferred strategy. A 70-year-old hypertensive diabetic woman has heart disease and asymptomatic chronic atrial fibrillation Decision analysis enables us to make multiple projection. For example, what would be the optimal (>3 months). Echocardiography shows enlarged left atrium and normal left ventricular function. She is at strategy in an elderly patient with a limited life expectancy due to severe comorbid conditions? And risk for thromboembolic events. If the patient is given oral anticoagulants, the risk of major haemorrhage if anticoagulation still remains the preferred strategy, what would be the magnitude of the gain yielded is increased, while the risk of systemic embolism is decreased. Either event can lead to one of three by this option? Only a few days? Similarly, what would be the effect of adding a third strategy with consequences: death, permanent morbidity, and/or short-term morbidity. Should oral anticoagulants be an intermediate efficacy (aspirin), assuming that if patients suffer a thromboembolic event while receivgiven? We used a standard computer program (Decision Maker)10 to construct a decision analysis ing antiplatelet drugs, their therapy is switched to oral anticoagulants? For patients with chronic atrial model representing recurrent events such as bleeding and/or embolism and their related consequences fibrillation, there is a wide range of risks for embolism and for bleeding, in addition to individual variables (morbidity), in addition to parameters such as patient's age, and mortality due to underlying cardiac such as age or patient's preference, making uniform recommendations very difficult, if not dangerous. disease, and we applied it to explore the consequences of giving or withholding anticoagulation Decision analysis allows us to explore each combination of these features, resulting in a unique patientin the setting of chronic atrial fibrillation. Such models, enabling projections about life expectancy, tailored decision.
achieved for what additional resource use (i.e. costDiscussion effectiveness analysis). The scope of randomized trials is limited by direct
In conclusion, the laudable purpose of making applicability only to non-representative 'average' clinical decisions based on evidence can be impaired patients. In response to these limitations, clinical by the difficulty in applying randomized trials-derived decision analysis allows us to create models that can data to a patient with his/her unique clinical features be applied to many different individuals encomand personal preferences. Decision analysis, by passing a wide variety of clinical scenarios (sensitivity allowing us to incorporate a patient's particular analyses). In these models, a single decision tree is clinical features, provides a useful mean of helping used, while patient-to-patient variability is captured health professionals to move from scientific evidence through a number of internal parameters. These to individualized decision making. It should therefore variables may include demographic data, such as be considered complementary to EBM. age-, sex-, and ethnicity-associated mortality rates; excess mortality attributable to coincident disease processes; or excess risks of treatment, to name a
